Ticker
BMY
Analysis
Bristol-myers Squibb Company (BMY) Stock Analysis
Bristol-myers Squibb Company investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to BMY.
Bristol-myers Squibb Company
Bristol-myers Squibb Company investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to BMY.
Stock profile
Asset type
Stock
Market cap
$110.27B
Sector
Health Technology
Industry
Pharmaceuticals: Major
Currency
USD
Ticker listings
Bristol-myers Squibb Company may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.
- BMY primary listing
- BRM
- 850501
- BMYB34
- 1BMY
- BMYD
- BMY.USD
- 0R1F
Latest Bristol-myers Squibb Company news
BREYANZI® CAR T Cell Therapy Monitoring and Activity Updates Approved in Canada
Bristol Myers Squibb Canada (BMS) is pleased to announce an update to the Canadian product monograph for BREYANZI® (lisocabtagene maraleucel), a CD19-directed chimeric antigen r...
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavac...
PRINCETON, N.J., June 01, 2026--US FDA Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos to Treat Adolescents with oHCM
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced...
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Sma...
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in R...
PRINCETON, N.J., May 29, 2026--BMS Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in....
Research sections
Valuation
Review valuation context for Bristol-myers Squibb Company.
Future growth
Review future growth context for Bristol-myers Squibb Company.
Past performance
Review past performance context for Bristol-myers Squibb Company.
Financial health
Review financial health context for Bristol-myers Squibb Company.
Dividend
Review dividend context for Bristol-myers Squibb Company.
Management
Review management context for Bristol-myers Squibb Company.
Ownership
Review ownership context for Bristol-myers Squibb Company.
Other information
Review other information context for Bristol-myers Squibb Company.
Community
Review community context for Bristol-myers Squibb Company.